文献速递血栓与止血MDS 与骨髓增殖性肿瘤

JAK2阳性骨髓增殖性肿瘤患者低剂量阿司匹林治疗中血栓与出血发生率:系统综述与荟萃分析

Incidence of thrombosis and bleeding in patients with JAK2- positive myeloproliferative neoplasms receiving low-dose aspirin: a systematic review and meta-analysis.
PubMed 文献 · J Thromb Haemost · 2026-10-17

该系统综述与荟萃分析纳入3项随机临床试验和7项观察性研究,评估JAK2V617F阳性MPN患者接受低剂量阿司匹林时血栓和出血事件发生率。结果显示阿司匹林与血栓风险降低相关(IRR 0.59),但出血风险增加(IRR 2.43),证据质量低。

要点

  • 低剂量阿司匹林使JAK2V617F阳性MPN患者血栓风险降低约40%。
  • 阿司匹林与出血风险增加约2.5倍相关。
  • 证据确定性低,需更多高质量研究明确阿司匹林角色。

核心结论

  • 阿司匹林与血栓风险降低40%相关,但出血风险增加2.5倍,证据确定性低。

研究设计与样本

  • 系统综述与荟萃分析,纳入3项随机临床试验和7项观察性研究,阿司匹林组1760例,非阿司匹林组367例。

主要发现

  • 接受低剂量阿司匹林的JAK2V617F阳性MPN患者血栓事件汇总发生率为2.72/100人年(95%CI 1.59-4.65;I2=93%)。
  • 阿司匹林对比非阿司匹林的血栓事件汇总发生率比为0.59(95%CI 0.40-0.86,I2=16%)。
  • 低剂量阿司匹林预防中主要和非主要出血汇总发生率为1.97/100人年(95%CI 1.06-3.65;I2=90%)。
  • 阿司匹林对比非阿司匹林的出血汇总发生率比为2.43(95%CI 1.15-5.11,I2=43%)。
  • GRADE证据确定性评估为低。

关键数值与推荐

  • 血栓事件汇总IR 2.72/100人年(95%CI 1.59-4.65;I2=93%)。
  • 血栓事件IRR 0.59(95%CI 0.40-0.86,I2=16%)。
  • 出血事件汇总IR 1.97/100人年(95%CI 1.06-3.65;I2=90%)。
  • 出血事件IRR 2.43(95%CI 1.15-5.11,I2=43%)。

临床怎么用

  • 对于JAK2V617F阳性MPN患者,低剂量阿司匹林可降低血栓风险但需警惕出血风险增加。
  • 临床决策应个体化权衡血栓与出血风险,并考虑证据确定性低。

局限性

  • 纳入研究异质性较高(血栓发生率I2=93%,出血发生率I2=90%)。
  • GRADE证据确定性为低。
  • 需要更多研究以获得高质量证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) are at increased thrombotic risk and commonly receive low-dose aspirin, yet its net clinical benefit is uncertain. OBJECTIVES: We estimated the incidence of thrombotic and bleeding events in patients with JAK2-positive MPNs treated with low-dose aspirin. METHODS: A systematic review was performed for studies evaluating thrombotic and hemorrhagic events in patients with JAK2V617F-positive MPNs while taking low-dose aspirin. Study-level incidence rates (IR) per 100 person-years (PY) and incidence rate ratios (IRR) comparing aspirin use versus no aspirin were calculated and pooled using random-effects meta-analysis. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. RESULTS: We included 3 randomized clinical trials and 7 observational studies (n=1,760 with aspirin, n=367 without aspirin). The pooled IR of thrombotic events in JAK2V617F-positive MPN patients receiving low-dose aspirin prophylaxis was 2.72 per 100 PY (95% confidence interval (CI) 1.59 - 4.65; I2=93%) with pooled IRR receiving aspirin versus no aspirin of 0.59 (95% CI 0.40 - 0.86, I2=16%). The pooled IR of major and non-major bleeding on low-dose aspirin prophylaxis was 1.97 (95% CI 1.06 - 3.65; I2=90%) per 100 PY with pooled IRR of 2.43 (95% CI 1.15 - 5.11; I2=43%). The GRADE level of confidence for the investigated risks was low. CONCLUSIONS: Aspirin was associated with a 40% reduction in thrombosis but a 2.5-fold increase in bleeding risk with low certainty of evidence. More studies are needed to gain high-quality evidence the better define the role of aspirin in JAK2V617F-positive MPNs.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Vrotniakaite-Bajerciene K, Marx CE, Tritschler T, et al. Incidence of thrombosis and bleeding in patients with JAK2- positive myeloproliferative neoplasms receiving low-dose aspirin: a systematic review and meta-analysis. J Thromb Haemost. 2026. PMID: 42892330. doi:10.1016/j.jtha.2026.09.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。